About Max

Dr. Max Ford serves as a toxicologist with CTEH. His background focuses on principles pertaining to molecular pharmacology, toxicology, virology, and veterinary diagnostics. Initially, Dr. Ford conducted his doctoral dissertation work at the University of Arkansas for Medical Sciences (UAMS) where he researched structure-activity relationships, receptor-mediated signaling processes, and in vivo pharmacological/toxicological effects of novel cannabinoid and opioid ligands. Following the completion of his dissertation at UAMS, he served as an ORISE postdoctoral fellow at the National Center for Toxicological Research where he investigated the molecular and behavioral neurotoxicological effects of anesthetic compounds in both rat and nonhuman primate research models. Before transitioning to CTEH, Dr. Ford served as the virology section supervisor at the Arkansas Veterinary Diagnostic Laboratory where he provided expertise in the field of molecular diagnostics for routine and regulatory diagnostic testing for poultry, livestock, and companion animal cases in Arkansas.

Dr. Ford’s role at CTEH is to provide expertise in environmental toxicology, emergency response, litigation support, and toxicological risk-assessment.

Registrations & Certifications

  • OSHA 40-Hour HAZWOPER

Publications

  • Reduced tolerance and asymmetrical cross-tolerance to effects of indole quinuclidinone analogue PNR-4-20, a G protein biased CB1R agonist in mice: comparisons with Delta9-THC and JWH-018., 2019
  • Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity., 2018
  • Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Delta(9)-THC., 2018
  • Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development., 2017
  • See All Publications
    • Reduced tolerance and asymmetrical cross-tolerance to effects of indole quinuclidinone analogue PNR-4-20, a G protein biased CB1R agonist in mice: comparisons with Delta9-THC and JWH-018., 2019
    • Selective Estrogen Receptor Modulators: Cannabinoid Receptor Inverse Agonists with Differential CB1 and CB2 Selectivity., 2018
    • Atypical Pharmacodynamic Properties and Metabolic Profile of the Abused Synthetic Cannabinoid AB-PINACA: Potential Contribution to Pronounced Adverse Effects Relative to Delta(9)-THC., 2018
    • Characterization of structurally novel G protein biased CB1 agonists: Implications for drug development., 2017
    • Synthetic Pot: Not Your Grandfather’s Marijuana., 2017
    • Antinociceptive effects of the 6-O-sulfate ester of morphine in normal and diabetic rats: Comparative role of mu- and delta-opioid receptors., 2016
    • The tamoxifen derivative ridaifen-B is a high affinity selective CB2 receptor inverse agonist exhibiting anti-inflammatory and anti-osteoclastogenic effects., 2016
    • Tamoxifen Isomers and Metabolites Exhibit Distinct Affinity and Activity at Cannabinoid Receptors: Potential Scaffold for Drug Development., 2016
    • Characterization of the intrinsic activity for a novel class of cannabinoid receptor ligands: Indole quinuclidine analogs., 2014
    • Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse., 2013
    • CB1 and CB2 receptors are novel molecular targets for Tamoxifen and 4OH-Tamoxifen., 2013
    • Evaluation of (Z)-2-((1-benzyl-1H-indol-3-yl)methylene)-quinuclidin-3-one analogues as novel, high affinity ligands for CB1 and CB2 cannabinoid receptors., 2013